Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).
Location: Finland, Mainland Finland, Helsinki
Employees: 11-50
Total raised: $10.57M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Advent Lif... | adventls.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.10.2020 | Series A | $10.57M | - |
Mentions in press and media 1
| Date | Title | Description |
| 13.10.2020 | Rappta Therapeutics Closes €9M Series A Financing | Rappta Therapeutics, a Helsinki, Finland-based company focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A), closed a €9m Series A financing. The round was co-led by Novartis Venture Fund and Novo ... |